Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial
Share
Listen to the news
Clearmind says CMND-100 meets primary safety endpoint in AUD Phase I/IIa trial
  • Clearmind Medicine reported positive top-line safety results from its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on April 20, 2026.
  • Data from third cohort showed drug candidate was well tolerated at highest dose tested so far, with no serious adverse events reported.
  • Study met its primary endpoint on safety and tolerability, supporting continued development of CMND-100 as a potential non-hallucinogenic oral treatment option for Alcohol Use Disorder.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200715PRIMZONEFULLFEED9692939) on April 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending